These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 7533866)

  • 1. Cytokine treatment of human bone marrow activates anti-leukaemia effector cells: monitoring of purging by polymerase chain reaction and DNA analysis.
    Dickinson AM; Middleton SL; Latham J; Dunn J; Thomas L; Proctor SJ
    Leukemia; 1995 Mar; 9(3):444-9. PubMed ID: 7533866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Culture of normal and leukemic bone marrow in interleukin-2: analysis of cell activation, cell proliferation, and cytokine production.
    Klingemann HG; Neerunjun J; Schwulera U; Ziltener HJ
    Leukemia; 1993 Sep; 7(9):1389-93. PubMed ID: 8371589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro sensitivity of post-bone marrow transplantation CFU-GM and BFU-E to TNF-alpha and IFN-gamma.
    Papadakis V; Ferguson KF; Heller G; Kernan NA
    Exp Hematol; 1995 Dec; 23(14):1422-30. PubMed ID: 8542927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-2 activation of human bone marrow in long-term cultures: an effective strategy for purging and generation of anti-tumor cytotoxic effectors.
    Verma UN; Bagg A; Brown E; Mazumder A
    Bone Marrow Transplant; 1994 Feb; 13(2):115-23. PubMed ID: 8205079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bcr-abl-positive and -negative clonogenic cells in CML patients undergoing long-term interferon treatment.
    Wandl UB; Bützler R; Niederle N; Kloke O; Mengelkoch B; Becher R; Seeber S; Opalka B
    Leukemia; 1994 May; 8(5):776-9. PubMed ID: 7514245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-2 inhibits proliferation of K562 cells and reduces accumulation of bcr/abl mRNA and oncoprotein.
    Dilloo D; Hanenberg H; Lion T; Burdach S
    Leukemia; 1995 Mar; 9(3):419-24. PubMed ID: 7885040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia.
    Scheffold C; Brandt K; Johnston V; Lefterova P; Degen B; Schöntube M; Huhn D; Neubauer A; Schmidt-Wolf IG
    Bone Marrow Transplant; 1995 Jan; 15(1):33-9. PubMed ID: 7538001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The effect of anti-bcr-abl hammerhead ribozyme on bone marrow purging].
    Wu Y; Chen YZ; Huang HF; Chen P; Lu LH
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Sep; 35(9):859-63. PubMed ID: 12958661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of various cytokines with interleukin 2 in the generation of killer cells from human bone marrow: application in purging of leukemia.
    Charak BS; Agah R; Gray D; Mazumder A
    Leuk Res; 1991; 15(9):801-10. PubMed ID: 1921458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients.
    Guo JQ; Lin H; Kantarjian H; Talpaz M; Champlin R; Andreeff M; Glassman A; Arlinghaus RB
    Leukemia; 2002 Dec; 16(12):2447-53. PubMed ID: 12454751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
    Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
    Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Influence of IFN-alpha and IFN-alpha combined with GM-CSF on expression of the genes related to cell apoptosis of MNCs from bone marrow in CML patients].
    Tang LJ; Chen HC; Peng XH
    Hunan Yi Ke Da Xue Xue Bao; 2000 Dec; 25(6):570-2. PubMed ID: 12516408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of bcr-abl mRNA in single progenitor colonies from patients with chronic myeloid leukemia by PCR: comparison with cytogenetics and PCR from uncultured cells.
    Schulze E; Krahl R; Thalmeier K; Helbig W
    Exp Hematol; 1995 Dec; 23(14):1649-54. PubMed ID: 8542960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.
    Carlo-Stella C; Dotti G; Mangoni L; Regazzi E; Garau D; Bonati A; Almici C; Sammarelli G; Savoldo B; Rizzo MT; Rizzoli V
    Blood; 1996 Oct; 88(8):3091-100. PubMed ID: 8874208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon.
    Lion T; Gaiger A; Henn T; Hörth E; Haas OA; Geissler K; Gadner H
    Leukemia; 1995 Aug; 9(8):1353-60. PubMed ID: 7643624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181).
    Estrov Z; Talpaz M; Zipf TF; Kantarjian HM; Ku S; Ouspenskaia MV; Hirsch-Ginsberg C; Huh Y; Yee G; Kurzrock R
    J Cell Physiol; 1996 Mar; 166(3):618-30. PubMed ID: 8600166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma.
    Broxmeyer HE; Williams DE; Lu L; Cooper S; Anderson SL; Beyer GS; Hoffman R; Rubin BY
    J Immunol; 1986 Jun; 136(12):4487-95. PubMed ID: 3086433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-2-activated cord blood mononuclear cells.
    Derzic S; Slone V; Sender L
    Cytotherapy; 2005; 7(5):408-16. PubMed ID: 16236630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.